title: Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?
authors.affiliation: 1 Laboratory of Pharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 2 Division of Nephrology-Hypertension, Antwerp University Hospital, B-2650 Edegem, Antwerp, Belgium ; 3 Laboratory of Physiopharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 4 Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610 Antwerp, Belgium.
authors.forename: Ilse
authors.initials: I
authors.lastname: Van Brussel
authors.affiliation: 1 Laboratory of Pharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 2 Division of Nephrology-Hypertension, Antwerp University Hospital, B-2650 Edegem, Antwerp, Belgium ; 3 Laboratory of Physiopharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 4 Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610 Antwerp, Belgium.
authors.forename: Amaryllis H
authors.initials: AH
authors.lastname: Van Craenenbroeck
authors.affiliation: 1 Laboratory of Pharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 2 Division of Nephrology-Hypertension, Antwerp University Hospital, B-2650 Edegem, Antwerp, Belgium ; 3 Laboratory of Physiopharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 4 Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610 Antwerp, Belgium.
authors.forename: Dorien M
authors.initials: DM
authors.lastname: Schrijvers
authors.affiliation: 1 Laboratory of Pharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 2 Division of Nephrology-Hypertension, Antwerp University Hospital, B-2650 Edegem, Antwerp, Belgium ; 3 Laboratory of Physiopharmacology, University of Antwerp, B-2610 Antwerp, Belgium ; 4 Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610 Antwerp, Belgium.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Cools
references.citation: J Leukoc Biol. 2007 Dec;82(6):1365-74
references.pmid: 17711977
references.citation: Clin Dev Immunol. 2010;2010:284581
references.pmid: 21253521
references.citation: J Exp Med. 2000 Jul 3;192(1):145-50
references.pmid: 10880536
references.citation: Cancer Res. 2003 May 1;63(9):2127-33
references.pmid: 12727829
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1099-105
references.pmid: 20100959
references.citation: Nat Med. 2012 Aug;18(8):1254-61
references.pmid: 22842478
references.citation: Immunity. 1994 Dec;1(9):751-61
references.pmid: 7895164
references.citation: Nat Rev Cancer. 2008 May;8(5):351-60
references.pmid: 18418403
references.citation: J Immunother. 2007 Oct;30(7):762-72
references.pmid: 17893568
references.citation: Vaccine. 2004 Jun 23;22(19):2362-7
references.pmid: 15193395
references.citation: Cancer Res. 2006 Jun 1;66(11):5910-8
references.pmid: 16740731
references.citation: Clin Exp Immunol. 1997 Sep;109(3):501-9
references.pmid: 9328129
references.citation: PLoS One. 2011 Apr 20;6(4):e18801
references.pmid: 21533099
references.citation: Int J Cancer. 2005 May 20;115(1):155-63
references.pmid: 15645438
references.citation: J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97
references.pmid: 20826737
references.citation: Nat Rev Urol. 2010 May;7(5):245-57
references.pmid: 20448658
references.citation: Int J Cancer. 1996 May 16;66(4):564-70
references.pmid: 8635875
references.citation: Mediators Inflamm. 2012;2012:690643
references.pmid: 22851815
references.citation: J Clin Invest. 1990 Mar;85(3):955-61
references.pmid: 2179270
references.citation: Blood. 2012 Jun 14;119(24):5688-96
references.pmid: 22555974
references.citation: Lancet Oncol. 2003 Apr;4(4):215-23
references.pmid: 12681265
references.citation: Clin Cancer Res. 2008 Jan 1;14(1):169-77
references.pmid: 18172268